You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Selective CB2 agonist (Ki values are 13.8 and 383 nM as measured at human cloned CB2 and CB1 receptors expressed in CHO cells).
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solubility||Soluble to 10 mM in DMSO and to 25 mM in ethanol|
References are publications that support the biological activity of the product.
Chin et al (1999) The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J.Pharmacol.Exp.Ther. 291 837 PMID: 10525107
Griffin et al (1997) Evidence for the presence of CB2-like receptor on peripheral nerve terminals. Eur.J.Pharmacol. 339 53 PMID: 9450616
Pertwee et al (1999) Pharmacology of cannabinoid receptor ligands. Curr.Med.Chem. 6 635 PMID: 10469884
If you know of a relevant reference for JWH 015, please let us know.
View Related Products by Product Action
Keywords: JWH 015, JWH 015 supplier, Selective, CB2, agonists, Cannabinoids, Receptors, JWH015, cb2r, 1341, Tocris Bioscience
21 Citations for JWH 015
Citations are publications that use Tocris products. Selected citations for JWH 015 include:
Sheng et al (2019) Antiallodynic Effects of Cannabinoid Receptor 2 (CB2R) Agonists on Retrovirus Infection-Induced Neuropathic Pain. Pain Res Manag 2019 1260353 PMID: 31354896
Robinson et al (2013) Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction. J Neuroimmune Pharmacol 8 1239 PMID: 23824763
Hervera et al (2010) The role of nitric oxide in the local antiallodynic and antihyperalgesic effects and expression of delta-opioid and cannabinoid-2 receptors during neuropathic pain in mice. J Pharmacol Exp Ther 334 887 PMID: 20498253
Small-Howard et al (2005) Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells. Biochem J 388 465 PMID: 15669919
Ehrhart et al (2005) Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2 29 PMID: 16343349
Price et al (2009) WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci 29 2177 PMID: 19490092
Lépicier et al (2003) Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol 139 805 PMID: 12813004
Fechtner et al (2019) Cannabinoid Receptor 2 Agonist JWH-015 Inhibits Interleukin-1β-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts and in Adjuvant Induced Arthritis Rat via Glucocorticoid Receptor. Front Immunol 10 1027 PMID: 31139184
Landry et al (2012) Spinal cannabinoid receptor type 2 agonist reduces mechanical allodynia and induces mitogen-activated protein kinase phosphatases in a rat model of neuropathic pain. J Pain 13 836 PMID: 22901764
Negrete et al (2011) The antinociceptive effects of JWH-015 in chronic inflammatory pain are produced by nitric oxide-cGMP-PKG-KATP pathway activation mediated by opioids. PLoS One 6 e26688 PMID: 22031841
McKallip et al (2002) Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100 627 PMID: 12091357
Ford et al (2002) Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol 135 1191 PMID: 11877326
Jiang et al Expression and function of cannabinoid receptors CB1 and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells. PLoS One 2 e641 PMID: 17653268
McGuinness et al (2009) Characterizing cannabinoid CB2 receptor ligands using DiscoveRx PathHunter β-arrestin assay. Mol Pharmacol 14 49 PMID: 19171920
Verty et al (2015) Anti-Obesity Effect of the CB2 Receptor Agonist JWH-015 in Diet-Induced Obese Mice. PLoS One 10 e0140592 PMID: 26588700
Preet et al (2011) Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. Cancer Prev Res (Phila) 4 65 PMID: 21097714
DiPatrizio et al (2011) Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci U S A 108 12904 PMID: 21730161
Ghosh et al (2018) The Endocannabinoid/Cannabinoid Receptor 2 System Protects Against Cisplatin-Induced Hearing Loss. Front Cell Neurosci 12 271 PMID: 30186120
Agudelo et al (2016) Alcohol and Cannabinoids Differentially Affect HIV Infection and Function of Human Monocyte-Derived Dendritic Cells (MDDC). Front Microbiol 6 1452 PMID: 26733986
Hanlon et al (2016) Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent. Breast Cancer (Dove Med Press) 8 59 PMID: 27186076
Börner et al (2006) Cannabinoid receptor type 2 agonists induce transcription of the mu-opioid receptor gene in Jurkat T cells. Mol Cell Neurosci 69 1486 PMID: 16434616
Do you know of a great paper that uses JWH 015 from Tocris? Please let us know.
Reviews for JWH 015
Average Rating: 5 (Based on 1 Review.)
Have you used JWH 015?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
We used all these compounds which were dissolved in DMSO and added to fresh culture media. Concentration reference paper PMID: 27186076
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.